{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T19:54:00Z","timestamp":1761854040386,"version":"build-2065373602"},"reference-count":16,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T00:00:00Z","timestamp":1670025600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nefrolog\u00eda (English Edition)"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.nefroe.2022.01.011","type":"journal-article","created":{"date-parts":[[2022,12,12]],"date-time":"2022-12-12T15:24:37Z","timestamp":1670858677000},"page":"636-639","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["D313Y variant in two related end-stage renal disease patients \u2013 Pathogenic or not yet?"],"prefix":"10.1016","volume":"43","author":[{"given":"Rita","family":"Vicente","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iolanda","family":"Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"Coimbra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joana","family":"Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricardo","family":"Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Amoedo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Pires","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nefroe.2022.01.011_bib0085","unstructured":"Disease TOMaMBoI. 150: \u03b1-galactosidase a deficiency: fabry disease. https:\/\/ommbid.mhmedical.com\/content.aspx?bookid=971&sectionid=62644837&jumpsectionID=62644922#1102896682."},{"key":"10.1016\/j.nefroe.2022.01.011_bib0090","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/01.md.0000178976.62537.6b","article-title":"The relationship of vascular glycolipid storage to clinical manifestations of Fabry disease: a cross-sectional study of a large cohort of clinically affected heterozygous women","volume":"84","author":"Gupta","year":"2005","journal-title":"Medicine"},{"key":"10.1016\/j.nefroe.2022.01.011_bib0095","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1365-2362.2004.01309.x","article-title":"Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey","volume":"34","author":"Mehta","year":"2004","journal-title":"Eur J Clin Invest"},{"year":"2001","series-title":"The metabolic and molecular bases of inherited disease","author":"Scriver","key":"10.1016\/j.nefroe.2022.01.011_bib0100"},{"key":"10.1016\/j.nefroe.2022.01.011_bib0105","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry disease","volume":"5","author":"Germain","year":"2010","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.nefroe.2022.01.011_bib0110","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1002\/humu.10275","article-title":"Fabry disease: characterization of alpha-galactosidase A double mutations and the D313Y plasma enzyme pseudodeficiency allele","volume":"22","author":"Yasuda","year":"2003","journal-title":"Hum Mutat"},{"key":"10.1016\/j.nefroe.2022.01.011_bib0115","doi-asserted-by":"crossref","first-page":"e010422","DOI":"10.1136\/bmjopen-2015-010422","article-title":"Organ manifestations and long-term outcome of Fabry disease in patients with the GLA haplotype D313Y","volume":"6","author":"Oder","year":"2016","journal-title":"BMJ Open"},{"key":"10.1016\/j.nefroe.2022.01.011_bib0120","first-page":"99","article-title":"Lyso-Gb3 indicates that the alpha-galactosidase a mutation D313Y is not clinically relevant for Fabry disease","volume":"7","author":"Niemann","year":"2013","journal-title":"JIMD Rep"},{"key":"10.1016\/j.nefroe.2022.01.011_bib0125","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1073\/pnas.0712309105","article-title":"Elevated globotriaosylsphingosine is a hallmark of Fabry disease","volume":"105","author":"Aerts","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.nefroe.2022.01.011_bib0130","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.pharmthera.2009.01.003","article-title":"Fabry disease","volume":"122","author":"Schiffmann","year":"2009","journal-title":"Pharmacol Therap"},{"key":"10.1016\/j.nefroe.2022.01.011_bib0135","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1016\/j.cca.2010.07.038","article-title":"How well does urinary lyso-Gb3 function as a biomarker in Fabry disease?","volume":"411","author":"Auray-Blais","year":"2010","journal-title":"Clin Chim Acta Int J Clin Chem"},{"key":"10.1016\/j.nefroe.2022.01.011_bib0140","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1080\/0886022X.2016.1254656","article-title":"Screening Fabry's disease in chronic kidney disease patients not on dialysis: a multicenter study","volume":"39","author":"Yenicerioglu","year":"2017","journal-title":"Ren Fail"},{"key":"10.1016\/j.nefroe.2022.01.011_bib0145","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/cge.13007","article-title":"The mutation p.D313Y is associated with organ manifestation in Fabry disease","volume":"92","author":"du Moulin","year":"2017","journal-title":"Clin Genet"},{"key":"10.1016\/j.nefroe.2022.01.011_bib0150","doi-asserted-by":"crossref","first-page":"e55565","DOI":"10.1371\/journal.pone.0055565","article-title":"Multifocal white matter lesions associated with the D313Y mutation of the alpha-galactosidase A gene","volume":"8","author":"Lenders","year":"2013","journal-title":"PLOS ONE"},{"key":"10.1016\/j.nefroe.2022.01.011_bib0155","doi-asserted-by":"crossref","first-page":"e017098","DOI":"10.1136\/bmjopen-2017-017098","article-title":"Fabry disease due to D313Y and novel GLA mutations","volume":"7","author":"Koulousios","year":"2017","journal-title":"BMJ Open"},{"key":"10.1016\/j.nefroe.2022.01.011_bib0160","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1136\/jmg.38.11.750","article-title":"Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males","volume":"38","author":"MacDermot","year":"2001","journal-title":"J Med Genet"}],"container-title":["Nefrolog\u00eda (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2013251422001602?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2013251422001602?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T19:50:34Z","timestamp":1761853834000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2013251422001602"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":16,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S2013251422001602"],"URL":"https:\/\/doi.org\/10.1016\/j.nefroe.2022.01.011","relation":{},"ISSN":["2013-2514"],"issn-type":[{"type":"print","value":"2013-2514"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"D313Y variant in two related end-stage renal disease patients \u2013 Pathogenic or not yet?","name":"articletitle","label":"Article Title"},{"value":"Nefrolog\u00eda (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nefroe.2022.01.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Sociedad Espa\u00f1ola de Nefrolog\u00eda. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}